Dimethyl fumarate - Only an anti-psoriatic medication?;Dimethylfumarat "nur" ein Anti-Psoriatikum?

JDDG - Journal of the German Society of Dermatology

Volumn 10, Issue 11, 2012, Pages 793-801

  Meissner, Markus ^a   Valesky, Eva Maria ^a   Kippenberger, Stefan ^a   Kaufmann, Roland ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

angiogenesis; dimethyl fumarate; multiple sclerosis; necrobiosis lipoidica; psoriasis; tumor

Indexed keywords

DERMATOLOGICAL AGENT; FUMARIC ACID DERIVATIVE; FUMARIC ACID DIMETHYL ESTER; IMMUNOSUPPRESSIVE AGENT;

GRANULOMA ANNULARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIPLE SCLEROSIS; NECROBIOSIS LIPOIDICA; NEOPLASM; OFF LABEL DRUG USE; REVIEW; SARCOIDOSIS;

DERMATOLOGIC AGENTS; FUMARATES; GRANULOMA ANNULARE; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; NECROBIOSIS LIPOIDICA; NEOPLASMS; OFF-LABEL USE; SARCOIDOSIS;

EID: 84868329304     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2012.07996.x     Document Type: Review

References (66)

1. Schweckendiek W,. Behandlung der Psoriasis vulgaris. Med Monatsschr 1959; 13: 103-4.
2. Litjens NH, van Strijen E, van Gulpen C, Mattie H, van Dissel JT, Thio HB, Nibbering PH,. In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. BMC Pharmacol 2004; 4: 22.
3. Rostami-Yazdi M, Clement B, Schmidt TJ, Schinor D, Mrowietz U,. Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. J Invest Dermatol 2009; 129: 231-4.
4. Rostami-Yazdi M, Clement B, Mrowietz U,. Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. Arch Dermatol Res 2010; 302: 531-8.
5. Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T,. Wirksamkeit und Sicherheit von Fumarsäureestern in der Langzeittherapie der Psoriasis-Eine retrospektive Studie (FUTURE). J Dtsch Dermatol Ges 2009; 7: 603-11.
6. Höxtermann S, Nuchel C, Altmeyer P,. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis. Dermatology 1998; 196: 223-30.
7. Bacharach-Buhles M, Pawlak FM, Matthes U, Joshi RK, Altmeyer P,. Fumaric acid esters (FAEs) suppress CD 15- and ODP 4-positive cells in psoriasis. Acta Derm Venereol Suppl (Stockh) 1994; 186: 79-82.
8. Hollins DL, Suliman HB, Piantadosi CA, Carraway MS,. Glutathione regulates susceptibility to oxidant-induced mitochondrial DNA damage in human lymphocytes. Free Radic Biol Med 2006; 40: 1220-6.
9. Ghoreschi K, Bruck J, Kellerer C, Deng C, Peng H, Rothfuss O, Hussain RZ, Gocke AR, Respa A, Glocova I, Valtcheva N, Alexander E, Feil S, Feil R, Schulze-Osthoff K, Rupec RA, Lovett-Racke AE, Dringen R, Racke MK, Röcken M,. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 2011; 208: 2291-303.
10. Treumer F, Zhu K, Glaser R, Mrowietz U,. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003; 121: 1383-8.
11. de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH,. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996; 26: 2067-74.
12. Gerdes S, Shakery K, Mrowietz U,. Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells. Br J Dermatol 2007; 156: 838-42.
13. Stoof TJ, Flier J, Sampat S, Nieboer C, Tensen CP, Boorsma DM,. The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol 2001; 144: 1114-20.
14. Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M,. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 1998; 139: 390-5.
15. Sebök B, Bonnekoh B, Vetter R, Schneider I, Gollnick H, Mahrle G,. The antipsoriatic dimethyl-fumarate suppresses interferon-gamma -induced ICAM-1 and HLA-DR expression on hyperproliferative keratinocytes. Quantification by a culture plate-directed APAAP-ELISA technique. Eur J Dermatol 1998; 8: 29-32.
16. Gesser B, Johansen C, Rasmussen MK, Funding AT, Otkjaer K, Kjellerup RB, Kragballe K, Iversen L,. Dimethylfumarate specifically inhibits the mitogen and stress-activated kinases 1 and 2 (MSK1/2): possible role for its anti-psoriatic effect. J Invest Dermatol 2007; 127: 2129-37.
17. Gesser B, Rasmussen MK, Raaby L, Rosada C, Johansen C, Kjellerup RB, Kragballe K, Iversen L,. Dimethylfumarate inhibits MIF-induced proliferation of keratinocytes by inhibiting MSK1 and RSK1 activation and by inducing nuclear p-c-Jun (S63) and p-p53 (S15) expression. Inflamm Res 2011; 60: 643-53.
18. Nelson KC, Carlson JL, Newman ML, Sternberg P, Jr., Jones DP, Kavanagh TJ, Diaz D, Cai J, Wu M,. Effect of dietary inducer dimethylfumarate on glutathione in cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1999; 40: 1927-35.
19. Zhu K, Mrowietz U,. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol 2001; 116: 203-8.
20. Wallbrecht K, Drick N, Hund AC, Schön MP,. Downregulation of endothelial adhesion molecules by dimethylfumarate, but not monomethylfumarate, and impairment of dynamic lymphocyte-endothelial cell interactions. Exp Dermatol 2011; 20: 980-5.
21. Meissner M, Doll M, Hrgovic I, Reichenbach G, König V, Hailemariam-Jahn T, Gille J, Kaufmann R,. Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action. J Invest Dermatol 2011; 131: 1356-64.
22. Wain EM, Darling MI, Pleass RD, Barker JN, Smith CH,. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study. Br J Dermatol 2010; 162: 427-34.
23. Gerdes S, Domm S, Mrowietz U,. Long-term treatment with fumaric acid esters in an 11-year-old male child with psoriasis. Dermatology 2011; 222: 198-200.
24. Günther C, Schmitt J, Wozel G,. Erfolgreicher Einsatz von Fumarsäureestern bei einer 14-jährigen Patientin mit Psoriasis vulgaris. Hautarzt 2004; 15: 28-30.
25. Rejdak K, Jackson S, Giovannoni G,. Multiple sclerosis: a practical overview for clinicians. Brit Med Bull 2010; 95: 79-104.
26. Wierinckx A, Breve J, Mercier D, Schultzberg M, Drukarch B, Van Dam AM,. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J Neuroimmunol 2005; 166: 132-43.
27. Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P, Zeng W, Ryan S, Yamamoto M, Lukashev M, Rhodes KJ,. Fumarates Promote Cytoprotection of Central Nervous System Cells Against Oxidative Stress via the Nrf2 Pathway. J Pharmacol Exp Ther 2012; 341: 274-84.
28. Schimrigk S, Brune N, Hellwig K, Lukas C, Bellenberg B, Rieks M, Hoffmann V, Pöhlau D, Przuntek H,. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 2006; 13: 604-10.
29. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN,; BG-12 Phase IIb Study Investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372: 1463-72.
30. MacManus DG, Miller DH, Kappos L, Gold R, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Eraksoy M, Meluzinova E, Dufek M, Yang M, O'Neill GN, Dawson K,. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol 2011; 258: 449-56.
31. Trial watch: Phase III success for Biogen's oral multiple sclerosis therapy. Nat Rev Drug Discov 2011; 10: 404.
32. Izikson L, English JC,. Noninfectious granulomatous diseases: an update. Adv Dermatol 2006; 22: 31-53.
33. Gambichler T, Kreuter A, Freitag M, Pawlak FM, Brockmeyer NH, Altmeyer P,. Clearance of necrobiosis lipoidica with fumaric acid esters. Dermatology 2003; 207: 422-4.
34. Kreuter A, Knierim C, Stücker M, Pawlak F, Rotterdam S, Altmeyer P, Gambichler T,. Fumaric acid esters in necrobiosis lipoidica: results of a prospective noncontrolled study. Br J Dermatol 2005; 153: 802-7.
35. Breuer K, Gutzmer R, Volker B, Kapp A, Werfel T,. Therapy of noninfectious granulomatous skin diseases with fumaric acid esters. Brit J Dermatol 2005; 152: 1290-5.
36. Eberle FC, Ghoreschi K, Hertl M,. Fumaric acid esters in severe ulcerative necrobiosis lipoidica: a case report and evaluation of current therapies. Acta Derm-Venereol 2010; 90: 104-6.
37. Cyr PR,. Diagnosis and management of granuloma annulare. Am Fam Physician 2006; 74: 1729-34.
38. Fayyazi A, Schweyer S, Eichmeyer B, Herms J, Hemmerlein B, Radzun HJ, Berger H,. Expression of IFN gamma, coexpression of TNF alpha and matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare. Archives of Dermatological Research 2000; 292: 384-90.
39. Eberlein-König B, Mempel M, Stahlecker J, Forer I, Ring J, Abeck D,. Disseminated granuloma annulare- treatment with fumaric acid esters. Dermatology 2005; 210: 223-6.
40. Weber HO, Borelli C, Röcken M, Schaller M,. Treatment of disseminated granuloma annulare with low-dose fumaric acid. Acta Derm Venereol 2009; 89: 295-8.
41. Schulze-Dirks A, Petzoldt D,. Granuloma annulare disseminatum: erfolgreiche Therapie mit Fumarsäurester. Hautarzt 2001; 52: 228-30.
42. Wollina U, Langner D,. Treatment of disseminated granuloma annulare recalcitrant to topical therapy: a retrospective 10-year analysis with comparison of photochemotherapy alone versus photochemotherapy plus oral fumaric acid esters. J Eur Acad Dermatol Venereol 2011; doi: 10.1111/j.1468-3083.2011. 04320.x [Epub ahead of print].
43. Ali MM, Atwan AA, Gonzalez ML,. Cutaneous sarcoidosis: updates in the pathogenesis. J Eur Acad Dermatol Venereol 2010; 24: 747-55.
44. Nowack U, Gambichler T, Hanefeld C, Kastner U, Altmeyer P,. Successful treatment of recalcitrant cutaneous sarcoidosis with fumaric acid esters. BMC Dermatol 2002; 2: 15.
45. Gutzmer R, Kapp A, Werfel T,. Erfolgreiche Therapie einer Haut- und Lungensarkoidose mit Fumarsäureestern. Hautarzt 2004; 55: 553-7.
46. Kleine R, Brohl L, Amon U,. Fumarsäureestertherapie bei einer jungen Patientin mit ausgeprägter Cheilitis granulomatosa. Hautarzt 2011; 62: 940-2.
47. Guenova E, Hötzenecker W,. Treatment of recurrent aphthous stomatitis with fumaric acid esters. Arch Dermatol 2011; 147: 282-4.
48. Venten I, Hess N, Hirschmüller A, Altmeyer P, Brockmeyer N,. Treatment of therapy-resistant Alopecia areata with fumaric acid esters. Eur J Med Res 2006; 11: 300-5.
49. Heinz C, Heiligenhaus A,. Improvement of noninfectious uveitis with fumaric acid esters: results of a pilot study. Arch Ophthalmol 2007; 125: 569-71.
50. Dethlefsen LA, Lehman CM, Biaglow JE, Peck VM,. Toxic effects of acute glutathione depletion by buthionine sulfoximine and dimethylfumarate on murine mammary carcinoma cells. Radiat Res 1988; 114: 215-24.
51. Kirlin WG, Cai J, DeLong MJ, Patten EJ, Jones DP,. Dietary compounds that induce cancer preventive phase 2 enzymes activate apoptosis at comparable doses in HT29 colon carcinoma cells. J Nutr 1999; 129: 1827-35.
52. Gu B, DeAngelis LM,. Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. Anticancer Drugs 2005; 16: 167-74.
53. Boivin A, Hanot M, Malesys C, Maalouf M, Rousson R, Rodriguez-Lafrasse C, Ardail D,. Transient alteration of cellular redox buffering before irradiation triggers apoptosis in head and neck carcinoma stem and non-stem cells. PLoS One 2011; 6: e14558.
54. Loewe R, Valero T, Kremling S, Pratscher B, Kunstfeld R, Pehamberger H, Petzelbauer P,. Dimethylfumarate impairs melanoma growth and metastasis. Cancer Res 2006; 66: 11888-96.
55. Valero T, Steele S, Neumüller K, Bracher A, Niederleithner H, Pehamberger H, Petzelbauer P,. Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis. J Invest Dermatol 2010; 130: 1087-94.
56. Yamazoe Y, Tsubaki M, Matsuoka H, Satou T, Itoh T, Kusunoki T, Kidera Y, Tanimori Y, Shoji K, Nakamura H, Ogaki M, Nishiura S, Nishida S,. Dimethylfumarate inhibits tumor cell invasion and metastasis by suppressing the expression and activities of matrix metalloproteinases in melanoma cells. Cell Biol Int 2009; 33: 1087-94.
57. Mattes J, Hulett M, Xie W, Hogan S, Rothenberg ME, Foster P, Parish C,. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 2003; 197: 387-93.
58. Miller AC, Gafner J, Clark EP, Samid D,. Posttranscriptional down-regulation of ras oncogene expression by inhibitors of cellular glutathione. Mol Cell Biol 1993; 13: 4416-22.
59. Barth D, Simon JC, Wetzig T,. Malignant melanoma during treatment with fumaric acid esters-coincidence or treatment-related J Dtsch Dermatol Ges 2011; 9: 223-5.
60. Jennings L, Murphy G,. Squamous cell carcinoma as a complication of fumaric acid ester immunosuppression. J Eur Acad Dermatol Venereol 2009; 23: 1451.
61. Ellrichmann G, Petrasch-Parwez E, Lee DH, Reick C, Arning L, Saft C, Gold R, Linker RA,. Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS One 2011; 6: e16172.
62. Ghashghaeinia M, Bobbala D, Wieder T, Koka S, Bruck J, Fehrenbacher B, Röcken M, Schaller M, Lang F, Ghoreschi K,. Targeting glutathione by dimethylfumarate protects against experimental malaria by enhancing erythrocyte cell membrane scrambling. Am J Physiol Cell Physiol 2010; 299: 791-804.
63. Cross SA, Cook DR, Chi AW, Vance PJ, Kolson LL, Wong BJ, Jordan-Sciutto KL, Kolson DL,. Dimethyl fumarate, an immune modulator and inducer of the antioxidant response, suppresses HIV replication and macrophage-mediated neurotoxicity: a novel candidate for HIV neuroprotection. J Immunol 2011; 187: 5015-25.
64. Seidel P, Goulet S, Hostettler K, Tamm M, Roth M,. DMF inhibits PDGF-BB induced airway smooth muscle cell proliferation through induction of heme-oxygenase-1. Respir Res 2010; 11: 145.
65. Meili-Butz S, Niermann T, Fasler-Kan E, Barbosa V, Butz N, John D, Brink M, Buser PT, Zaugg CE,. Dimethyl fumarate, a small molecule drug for psoriasis, inhibits Nuclear Factor-kappaB and reduces myocardial infarct size in rats. Eur J Pharmacol 2008; 586: 251-8.
66. Seidel P, Merfort I, Hughes JM, Oliver BG, Tamm M, Roth M,. Dimethylfumarate inhibits NF-I°B function at multiple levels to limit airway smooth muscle cell cytokine secretion. Am J Physiol Lung Cell Mol Physiol 2009; 297: 326-39.